<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of topical disodium cromoglycate (DSCG) has been examined in 30 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> active <z:mp ids='MP_0003305'>proctitis</z:mp> using a double-blind crossover trial </plain></SENT>
<SENT sid="1" pm="."><plain>Each treatment period was four weeks and patients were given DSCG 200 mg by enema twice daily and 100 mg orally three times each day </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-six patients completed the trial successfully, 14 responded to DSCG treatment, two improved with placebo, and 10 responded to neither </plain></SENT>
<SENT sid="3" pm="."><plain>Patients who responded to DSCG had significantly more eosinophils in their rectal biopsies than those who failed to respond and in some instances the counts were very high </plain></SENT>
<SENT sid="4" pm="."><plain>The findings support the hypothesis than an allergic reaction is important in the pathogenesis of <z:mp ids='MP_0003305'>proctitis</z:mp> </plain></SENT>
</text></document>